Symbiotec Pharmalab IPO Day 1: Subscription status, review — here's what you need to know
- Symbiotec Pharmalab IPO opened on August 24, 2026, with a total subscription of 0.26x on Day 1.
- NII (bHNI) category showed strong momentum, jumping 86.2% to 0.54x by end of day.
- Retail subscription increased by 90.0% to 0.38x, while QIBs remained at 0.00x.
- The company reported FY 2026 revenue of ₹869.15 crores and profit of ₹109.90 crores.
- Issue proceeds will be used for repayment of borrowings (₹112.50 crores) and general corporate purposes.
*this image is generated using AI for illustrative purposes only.
Symbiotec Pharmalab’s IPO opened today, August 24, 2026. On Day 1, the issue was subscribed 0.26x overall. Non-Institutional Buyers (bHNI) led the late-day surge at 0.54x, while QIBs remained inactive at 0.00x. Retail investors subscribed 0.38x.
Subscription Status
The issue saw significant intraday momentum in the afternoon session. While QIBs remained dormant throughout the day, individual investors picked up pace after 12:15 PM.
| Category | Subscription Multiple |
|---|---|
| QIB | 0.00x |
| NII (bHNI) | 0.54x |
| NII (sHNI) | 0.21x |
| Retail | 0.38x |
| Employees | 0.61x |
| Total | 0.26x |
Intra-day Timeline (24-08-2026)
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 11:15 | 0.00x | 0.29x | 0.20x | 0.14x |
| 12:15 | 0.00x | 0.54x | 0.38x | 0.26x |
Momentum Highlights
- NII (bHNI) jumped +86.2% today (from 0.29x to 0.54x)
- Retail jumped +90.0% today (from 0.20x to 0.38x)
- Total jumped +85.7% today (from 0.14x to 0.26x)
About the Company
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company founded in 2002. It operates across organic chemistry, biotechnology, and complex injectables platforms. The company holds a global leadership position in corticosteroid APIs with a 38.2% volume market share. Promoters include Anil Satwani (MD), Rohit Mantri (Director), Sunita Kishnani (Director), Pratik Patel (Director), and Pramod Kasat (Director).
Financial Highlights
| Particulars | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue from Operations (₹ crores) | 869.15 | 751.55 | 716.25 |
| Total Profit (₹ crores) | 109.90 | 96.79 | 100.06 |
| Total Equity (₹ crores) | 1149.59 | 814.71 | 714.84 |
The company reported revenue of ₹869.15 crores and a total profit of ₹109.90 crores in FY 2026. Total equity stood at ₹1149.59 crores as of March 31, 2026.
Objects of the Issue
- Prepayment and/or repayment of outstanding borrowings: ₹112.50 crores
- General corporate purposes: Balance net proceeds
Risk Factors
- High Revenue Concentration in APIs: Almost all revenue derived from API sales.
- Regulatory Compliance Risks: Subject to periodic inspections; recent US FDA Form 483 observations.
- Significant Export Revenue Exposure: ~67% revenue from external customers outside India.
Offer Details
- Price Band: ₹938.00000 - ₹988.00000
- Issue Size: 13470 - 500000
- Min Bid Qty: 15
- Open Date: 2026-08-24
- Close Date: 2026-08-27
How might the complete lack of QIB participation on Day 1 impact the final subscription status and potential listing gains by the close date?
What specific remedial actions is Symbiotec Pharmalab taking to address the recent US FDA Form 483 observations, and how could this affect future export approvals?
Given that nearly all revenue is derived from APIs, how vulnerable is the company's growth trajectory to potential price compression in the corticosteroid segment?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
